Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria (Q38692072)

5 September 2017

title

Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria (English)

1 reference

5 September 2017

main subject

gram-positive bacteria

0 references

1 reference

Kristin E Linder

1

1 reference

5 September 2017

David P Nicolau

series ordinal

2

1 reference

5 September 2017

Michael D Nailor

series ordinal

3

1 reference

5 September 2017

language of work or name

English

0 references

publication date

11 January 2016

1 reference

Expert Opinion on Drug Metabolism & Toxicology

5 September 2017

published in

1 reference

5 September 2017

volume

12

1 reference

5 September 2017

issue

3

1 reference

5 September 2017

page(s)

267-280

1 reference

The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Improving predictions of the risk of resistance development against new and old antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

The intrinsic resistome of Pseudomonas aeruginosa to β-lactams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

The neglected intrinsic resistome of bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Evolutionary trajectories of beta-lactamase CTX-M-1 cluster enzymes: predicting antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

The mutant selection window and antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Use of Monte Carlo simulation to evaluate the development of vancomycin resistance in meticillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

New antimicrobial agents as therapy for resistant gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Linezolid resistance in clinical isolates of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

New uses for new and old quinolones and the challenge of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Influence of macrolide antibiotics on promotion of resistance in the oral flora of children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by beta-lactam physiological concentrations over time: an in vitro pharmacodynamic simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Enterococcus faecalis resistant to linezolid: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Emergence of Daptomycin-Resistant VRE: Experience of a Single Institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Genetic basis for in vivo daptomycin resistance in enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141197

10.1517/17425255.2016.1141197

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference